Tudor Investment Corp ET AL Increases Stock Position in Privia Health Group, Inc. (NASDAQ:PRVA)

Tudor Investment Corp ET AL raised its position in shares of Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 16.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 267,899 shares of the company's stock after purchasing an additional 37,904 shares during the period. Tudor Investment Corp ET AL owned approximately 0.22% of Privia Health Group worth $5,237,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Two Sigma Securities LLC purchased a new position in shares of Privia Health Group during the 4th quarter valued at about $463,000. Voya Investment Management LLC raised its stake in shares of Privia Health Group by 4.7% during the fourth quarter. Voya Investment Management LLC now owns 212,342 shares of the company's stock worth $4,151,000 after acquiring an additional 9,539 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Privia Health Group by 15.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 73,416 shares of the company's stock worth $1,436,000 after acquiring an additional 9,880 shares during the last quarter. BlackBarn Capital Partners LP boosted its stake in shares of Privia Health Group by 65.8% in the 4th quarter. BlackBarn Capital Partners LP now owns 663,397 shares of the company's stock valued at $12,969,000 after purchasing an additional 263,397 shares in the last quarter. Finally, State of Tennessee Department of Treasury grew its holdings in shares of Privia Health Group by 18.1% during the 4th quarter. State of Tennessee Department of Treasury now owns 57,075 shares of the company's stock valued at $1,116,000 after purchasing an additional 8,733 shares during the last quarter. Institutional investors own 94.48% of the company's stock.

Insiders Place Their Bets

In other Privia Health Group news, Director Matthew Shawn Morris sold 10,309 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $23.33, for a total transaction of $240,508.97. Following the completion of the transaction, the director now owns 59,792 shares of the company's stock, valued at approximately $1,394,947.36. This trade represents a 14.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO David Mountcastle sold 3,445 shares of the business's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $23.33, for a total value of $80,371.85. Following the completion of the sale, the chief financial officer now directly owns 176,231 shares in the company, valued at approximately $4,111,469.23. This represents a 1.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 34,484 shares of company stock worth $799,163. 10.70% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Barclays raised their price objective on Privia Health Group from $21.00 to $23.00 and gave the company an "equal weight" rating in a research note on Thursday, April 10th. Robert W. Baird boosted their price objective on Privia Health Group from $24.00 to $26.00 and gave the company an "outperform" rating in a research report on Tuesday, April 15th. Truist Financial raised their target price on shares of Privia Health Group from $27.00 to $28.00 and gave the stock a "buy" rating in a report on Thursday, April 10th. Canaccord Genuity Group upped their price target on shares of Privia Health Group from $29.00 to $30.00 and gave the company a "buy" rating in a report on Friday, February 28th. Finally, Piper Sandler raised their price target on shares of Privia Health Group from $25.00 to $40.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. One investment analyst has rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $27.38.

Privia Health Group Stock Down 1.4 %

Shares of NASDAQ:PRVA traded down $0.33 during trading on Tuesday, hitting $22.65. The stock had a trading volume of 76,444 shares, compared to its average volume of 766,815. The company has a market capitalization of $2.75 billion, a PE ratio of 226.72, a PEG ratio of 3.47 and a beta of 0.87. The firm's fifty day moving average is $23.47 and its 200 day moving average is $22.16. Privia Health Group, Inc. has a 12 month low of $15.92 and a 12 month high of $26.04.

Privia Health Group Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.